Single-ingredient pharmaceutical exemption and brand-name classification hinge on inert aids and manufacturer markings, not proprietary character.

A pharmaceutical preparation may still qualify as a single-ingredient formulation for exemption where a pharmaceutical aid is used only as a therapeutically inert vehicle or isotonic medium and does not affect the drug's therapeutic or prophylactic activity. On that basis, the products were treated as eligible for concessional duty under Notification No. 29/88-C.E. The text also states that embossed manufacturer identification on the bottles amounted only to a house mark and did not create a brand name or proprietary connection, so the products were not patent or proprietary medicaments under Chapter 30. As the duty demand failed on merits, penalty was not sustainable and limitation did not require separate adjudication.

---

---

Issues: (i) Whether the appellants were entitled to concessional duty under Notification No. 29/88-C.E. for the products cleared during the relevant period; (ii) whether the products were classifiable as patent or proprietary medicaments under Chapter 30; (iii) whether penalty was imposable and the demand was barred by limitation.

Issue (i): Whether the appellants were entitled to concessional duty under Notification No. 29/88-C.E. for the products cleared during the relevant period.

Analysis: The notification applied to single ingredient formulations based on bulk drugs, with pharmaceutical aids permitted only if they were therapeutically inert and did not interfere with the therapeutic or prophylactic activity of the drug. The composition of the products showed sodium chloride was used in combination with metronidazole and functioned as a vehicle/isotonic medium rather than as an active therapeutic ingredient. On that basis, the product satisfied the notification requirement of a single ingredient formulation for the purposes of exemption.

Conclusion: The appellants were entitled to the concessional rate of duty under Notification No. 29/88-C.E.

Issue (ii): Whether the products were classifiable as patent or proprietary medicaments under Chapter 30.

Analysis: Classification as patent or proprietary medicaments depended on whether the preparation bore a name, mark, symbol, monogram, label or other feature establishing a proprietary connection with the manufacturer beyond compulsory identification under the drug rules. The embossed letters on the bottles were treated only as a house mark identifying the manufacturer and not as a brand name or product mark. The products therefore did not acquire the character of patent or proprietary medicaments.

Conclusion: The products were not patent or proprietary medicaments and were not classifiable under the disputed tariff heading on that basis.

Issue (iii): Whether penalty was imposable and the demand was barred by limitation.

Analysis: Once the products were held eligible for concessional duty and not classifiable as patent or proprietary medicaments, no case remained for penal action. In the absence of any short levy, the question of limitation did not arise for separate adjudication.

Conclusion: Penalty was not sustainable and limitation became irrelevant.

Final Conclusion: The impugned order was set aside and the appeal was allowed in full, with the duty demand and penalty failing on merits.

Ratio Decidendi: A pharmaceutical preparation using a pharmaceutical aid only as a therapeutically inert vehicle or isotonic medium remains within a single ingredient formulation for exemption purposes, and compulsory manufacturer identification on the container does not by itself make the medicine patent or proprietary.

---